Advanced in Proctitis

Dr. Harry Sarles

Gastroenterology
Office
3144 Horizon Rd Ste 210, 
Rockwall, TX 
47 Years of Experience
Advanced in Proctitis
Office
3144 Horizon Rd Ste 210, 
Rockwall, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Harry Sarles is a Gastroenterologist in Rockwall, Texas. Dr. Sarles has been practicing medicine for over 47 years and is rated as an Advanced provider by MediFind in the treatment of Proctitis. His top areas of expertise are Familial Adenomatous Polyposis, Portal Hypertension, Childhood Volvulus, Ulcerative Colitis, and Gastrectomy.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1979
Specialties
Gastroenterology
Licenses
Internal Medicine in TX
Hospital Affiliations
Texas Health Presbyterian Hospital Rockwall
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Office
3144 Horizon Rd Ste 210, Rockwall, TX 75032

Additional Areas of Focus

Dr. Sarles has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
AIDA: A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Clinical Efficacy and Safety of Artificial Intelligence (AI) Detection of Adenomas (AIDA) With Standard High Definition With Light in Screening Colonoscopy
AIDA: A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Clinical Efficacy and Safety of Artificial Intelligence (AI) Detection of Adenomas (AIDA) With Standard High Definition With Light in Screening Colonoscopy
Enrollment Status: Unknown
Publish Date: March 19, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Distinguished in Proctitis
Dr. Vinay Antin
Gastroenterology
Distinguished in Proctitis
Dr. Vinay Antin
Gastroenterology

Office

4375 Booth Calloway Rd Ste 307, 
North Richland Hills, TX 
 (43.5 miles away)
682-463-0400
Languages Spoken:
English
See accepted insurances

Vinay Antin is a Gastroenterologist in North Richland Hills, Texas. Dr. Antin is rated as an Advanced provider by MediFind in the treatment of Proctitis. His top areas of expertise are Chronic Erosive Gastritis, Proctitis, Gastroesophageal Reflux Disease (GERD), Gastrectomy, and Endoscopy.

Advanced in Proctitis
Dr. Alexander Mantas
Gastroenterology | Internal Medicine
Advanced in Proctitis
Dr. Alexander Mantas
Gastroenterology | Internal Medicine

Texas Digestive Disease Consultants

12200 Park Central Dr, Ste 403, 
Dallas, TX 
 (18.0 miles away)
972-617-2000
Languages Spoken:
English
See accepted insurances

Alexander Mantas is an Internal Medicine specialist and a Gastroenterologist in Dallas, Texas. Dr. Mantas is rated as a Distinguished provider by MediFind in the treatment of Proctitis. His top areas of expertise are Gastrointestinal Bleeding, Heartburn, Proctitis, Gas Bloat Syndrome, and Gastrectomy.

Advanced in Proctitis
Dr. Stuart Akerman
Gastroenterology | Internal Medicine
Advanced in Proctitis
Dr. Stuart Akerman
Gastroenterology | Internal Medicine

Digestive Health Associates Of Texas - Plano

3242 Preston Rd, Ste 200, 
Plano, TX 
 (21.8 miles away)
972-867-0019
Languages Spoken:
English
See accepted insurances

Stuart Akerman is an Internal Medicine specialist and a Gastroenterologist in Plano, Texas. Dr. Akerman is rated as a Distinguished provider by MediFind in the treatment of Proctitis. His top areas of expertise are Heartburn, Gastroesophageal Reflux Disease (GERD), Gas Bloat Syndrome, Endoscopy, and Gastrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sarles's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile